Specific post-marketing surveillance of pazufloxacin (Pasil), an injectable antimicrobial
Not Applicable
- Conditions
- sepsis, severe or intractable respiratory tract infections (pneumonia, secondary infection of chronic respiratory diseases), or the pneumonia caused by Streptococcus pneumoniae
- Registration Number
- JPRN-jRCT1080222732
- Lead Sponsor
- Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
1. Target disease: sepsis, severe or intractable respiratory tract infections (pneumonia, secondary infection of chronic respiratory diseases), or the pneumonia caused by Streptococcus pneumoniae
2. Age: 15 years of age and older
3. Gender : Both
4. Patients administered at a dose of 1,000 mg twice daily
5. Others
Exclusion Criteria
1. Patients in whom drug efficacy of pazufloxacin (Pasil) was difficult to assess
2. Others
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method